Ceruvia Lifesciences Submits FDA Investigational New Drug Application for Psilocybin Obsessive-Compulsive Disorder Program

Based on a positive pre-IND meeting with the U.S. FDA, Ceruvia Lifesciences has submitted an Investigation New Drug (IND) application to begin a Phase II clinical trial for the treatment of obsessive-compulsive disorder with psilocybin

Preliminary results from the Ceruvia funded pilot Phase II study taking place at Yale School of Medicine demonstrate rapid and robust improvement in OCD symptoms with a sustained effect.

Topic Obsessive-Compulsive Disorder

Compound Psilocybin

Visit article

Category Press Release

Published in Cision

Companies Featured

Ceruvia Lifesciences
Ceruvia Lifesciences are researching, developing and manufacturing novel psychedelic compounds for the treatment of hard-to-treat disorders including headache disorders and Obsessive Compulsive Disorder (OCD).

Yale University
The Yale Psychedelic Science Group was established in 2016.